Difference between revisions of "Part:BBa K3132022"

 
(→‎A scFv derevied from Hercetin)
 
(One intermediate revision by the same user not shown)
Line 4: Line 4:
  
 
This part is a second-generation chimeric antigen receptor, whose scFV segment is derived from trastuzumab. Therefore, this part can target EGFR。
 
This part is a second-generation chimeric antigen receptor, whose scFV segment is derived from trastuzumab. Therefore, this part can target EGFR。
 +
 +
 +
 +
==NUM_China 2021==
 +
=== A scFv derevied from Herceptin===
 +
 +
This parts contains an scFv derived from the famous antibody trastuzumab, which sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor-positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.Therefore the above description is wrong, it can target HER2.
 +
 +
Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000. It is on the World Health Organization's List of Essential Medicines. A biosimilar was approved in the European Union in November 2017, and in the United States in December 2018.
 +
 +
 +
 +
<div><ul>
 +
<center>
 +
  <li style="display: inline-block;"> [[File:T--NMU_China--TTZ.png|thumb|none|400px|<b>Figure 1:</b> Trastuzumab Fab region (cyan) binding HER2/neu (gold) available in PDB.]] </li>
 +
</center>
 +
    </ul></div>
 +
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here

Latest revision as of 03:36, 2 October 2021


trastuzumab4D5-5 scFv-CAR

This part is a second-generation chimeric antigen receptor, whose scFV segment is derived from trastuzumab. Therefore, this part can target EGFR。


NUM_China 2021

A scFv derevied from Herceptin

This parts contains an scFv derived from the famous antibody trastuzumab, which sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor-positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.Therefore the above description is wrong, it can target HER2.

Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000. It is on the World Health Organization's List of Essential Medicines. A biosimilar was approved in the European Union in November 2017, and in the United States in December 2018.


  • Figure 1: Trastuzumab Fab region (cyan) binding HER2/neu (gold) available in PDB.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal NotI site found at 971
    Illegal NotI site found at 1208
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 847
    Illegal NgoMIV site found at 916
  • 1000
    COMPATIBLE WITH RFC[1000]